Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan-Reference-Cited by-同舟云学术

Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan

Published:2024-08 Issue:8 Volume:30 Page:716-724
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Mizuno Takahito^ORCID,Kondo Yu^ORCID,Sakai Mikiyasu^ORCID,Saneyasu Kenichi,Kojima Ryota,Miyake Yoshio

Publisher

Elsevier BV

Reference39 articles.

1. The Japanese Association for Infectious Diseases. Concept of drug treatment for COVID-19 15.1th edition published 21 Feb 2023 [in Japanese]. 2023https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_drug_230217.pdf. [Accessed 13 Aug 2023].

2. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19;Hammond;N Engl J Med,2022

3. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study;Aggarwal;Lancet Infect Dis,2023

4. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019;Ganatra;Clin Infect Dis,2023

5. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system;Lewnard;Lancet Infect Dis,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNA replication-independent, DNA linearization-dependent expression of reporter genes from a SARS-CoV-2 replicon-encoding DNA in human cells;PLOS ONE;2024-08-16